-
1
-
-
0037396214
-
Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
-
Owen RG, Treon SP, Al-Katib A, et al: Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30: 110-115, 2003
-
(2003)
Semin Oncol
, vol.30
, pp. 110-115
-
-
Owen, R.G.1
Treon, S.P.2
Al-Katib, A.3
-
3
-
-
0032520265
-
Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994
-
Groves FD, Travis LB, Devesa SS, et al: Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994. Cancer 82: 1078-1081, 1998
-
(1998)
Cancer
, vol.82
, pp. 1078-1081
-
-
Groves, F.D.1
Travis, L.B.2
Devesa, S.S.3
-
4
-
-
79953699058
-
Associated malignancies in patients with Waldenström's macroglobulinemia and their kin
-
Hanzis C, Ojha RP, Hunter Z, et al: Associated malignancies in patients with Waldenström's macroglobulinemia and their kin. Clin Lymphoma Myeloma Leuk 11: 88-92, 2011
-
(2011)
Clin Lymphoma Myeloma Leuk
, vol.11
, pp. 88-92
-
-
Hanzis, C.1
Ojha, R.P.2
Hunter, Z.3
-
5
-
-
84856362228
-
Risk of second cancers in Waldenström macroglobulinemia
-
Varettoni M, Tedeschi A, Arcaini L, et al: Risk of second cancers in Waldenström macroglobulinemia. Ann Oncol 23: 411-415, 2012
-
(2012)
Ann Oncol
, vol.23
, pp. 411-415
-
-
Varettoni, M.1
Tedeschi, A.2
Arcaini, L.3
-
6
-
-
33644681507
-
Characterization of familial Waldenstrom's macroglobulinemia
-
Treon SP, Hunter ZR, Aggarwal A, et al: Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 17: 488-494, 2006
-
(2006)
Ann Oncol
, vol.17
, pp. 488-494
-
-
Treon, S.P.1
Hunter, Z.R.2
Aggarwal, A.3
-
7
-
-
54049129700
-
Risk of lymphoproliferative disorders among firstdegree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A populationbased study in Sweden
-
Kristinsson SY, Björkholm M, Goldin LR, et al: Risk of lymphoproliferative disorders among firstdegree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: A populationbased study in Sweden. Blood 112: 3052-3056, 2008
-
(2008)
Blood
, vol.112
, pp. 3052-3056
-
-
Kristinsson, S.Y.1
Björkholm, M.2
Goldin, L.R.3
-
8
-
-
34548830816
-
Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families
-
McMaster ML, Csako G, Giambarresi TR, et al: Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families. Clin Cancer Res 13: 5063-5069, 2007
-
(2007)
Clin Cancer Res
, vol.13
, pp. 5063-5069
-
-
McMaster, M.L.1
Csako, G.2
Giambarresi, T.R.3
-
9
-
-
0032854758
-
Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2
-
Ogmundsdóttir HM, Sveinsdóttir S, Sigfússon A, et al: Enhanced B cell survival in familial macroglobulinaemia is associated with increased expression of Bcl-2. Clin Exp Immunol 117: 252-260, 1999
-
(1999)
Clin Exp Immunol
, vol.117
, pp. 252-260
-
-
Ogmundsdóttir, H.M.1
Sveinsdóttir, S.2
Sigfússon, A.3
-
10
-
-
84974621496
-
Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia
-
Roccaro AM, Sacco A, Shi J, et al: Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood 127: 2598-2606, 2016
-
(2016)
Blood
, vol.127
, pp. 2598-2606
-
-
Roccaro, A.M.1
Sacco, A.2
Shi, J.3
-
11
-
-
84869472021
-
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia
-
Treon SP, Tripsas C, Hanzis C, et al: Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk 12: 433-437, 2012
-
(2012)
Clin Lymphoma Myeloma Leuk
, vol.12
, pp. 433-437
-
-
Treon, S.P.1
Tripsas, C.2
Hanzis, C.3
-
12
-
-
84926193835
-
Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival
-
Steingrímsson V, Lund SH, Turesson I, et al: Population-based study on the impact of the familial form of Waldenström macroglobulinemia on overall survival. Blood 125: 2174-2175, 2015
-
(2015)
Blood
, vol.125
, pp. 2174-2175
-
-
Steingrímsson, V.1
Lund, S.H.2
Turesson, I.3
-
13
-
-
0037108295
-
Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions
-
Schop RF, Kuehl WM, Van Wier SA, et al: Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood 100: 2996-3001, 2002
-
(2002)
Blood
, vol.100
, pp. 2996-3001
-
-
Schop, R.F.1
Kuehl, W.M.2
Van Wier, S.A.3
-
14
-
-
33845501643
-
6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis
-
Ocio EM, Schop RF, Gonzalez B, et al: 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 136: 80-86, 2007
-
(2007)
Br J Haematol
, vol.136
, pp. 80-86
-
-
Ocio, E.M.1
Schop, R.F.2
Gonzalez, B.3
-
15
-
-
67649566146
-
Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: A multicenter study
-
Chang H, Qi C, Trieu Y, et al: Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: A multicenter study. Clin Lymphoma Myeloma 9: 36-38, 2009
-
(2009)
Clin Lymphoma Myeloma
, vol.9
, pp. 36-38
-
-
Chang, H.1
Qi, C.2
Trieu, Y.3
-
16
-
-
84875653870
-
Chromosomal aberrations and their prognostic value in a series of 174 untreated patients withWaldenström's macroglobulinemia
-
Nguyen-Khac F, Lambert J, Chapiro E, et al: Chromosomal aberrations and their prognostic value in a series of 174 untreated patients withWaldenström's macroglobulinemia. Haematologica 98: 649-654, 2013
-
(2013)
Haematologica
, vol.98
, pp. 649-654
-
-
Nguyen-Khac, F.1
Lambert, J.2
Chapiro, E.3
-
17
-
-
0036203951
-
Trisomy 4 as the sole cytogenetic abnormality in a Waldenström macroglobulinemia
-
Rivera AI, Li MM, Beltran G, et al: Trisomy 4 as the sole cytogenetic abnormality in a Waldenström macroglobulinemia. Cancer Genet Cytogenet 133: 172-173, 2002
-
(2002)
Cancer Genet Cytogenet
, vol.133
, pp. 172-173
-
-
Rivera, A.I.1
Li, M.M.2
Beltran, G.3
-
18
-
-
0037397404
-
14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia
-
Avet-Loiseau H, Garand R, LodéL, et al: 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 30: 153-155, 2003
-
(2003)
Semin Oncol
, vol.30
, pp. 153-155
-
-
Avet-Loiseau, H.1
Garand, R.2
Lodé, L.3
-
19
-
-
84865475885
-
MYD88 L265P somatic mutation in Waldenström's macroglobulinemia
-
Treon SP, Xu L, Yang G, et al: MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med 367: 826-833, 2012
-
(2012)
N Engl J Med
, vol.367
, pp. 826-833
-
-
Treon, S.P.1
Xu, L.2
Yang, G.3
-
20
-
-
84877343691
-
MYD88 L265P inWaldenströmmacroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
-
Xu L, Hunter ZR, Yang G, et al: MYD88 L265P inWaldenströmmacroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 121: 2051-2058, 2013
-
(2013)
Blood
, vol.121
, pp. 2051-2058
-
-
Xu, L.1
Hunter, Z.R.2
Yang, G.3
-
21
-
-
84878423649
-
Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
-
Varettoni M, Arcaini L, Zibellini S, et al: Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 121: 2522-2528, 2013
-
(2013)
Blood
, vol.121
, pp. 2522-2528
-
-
Varettoni, M.1
Arcaini, L.2
Zibellini, S.3
-
22
-
-
84881482021
-
MYD88 L265P is amarker highly characteristic of, but not restricted to,Waldenström's macroglobulinemia
-
Jiménez C, Sebastián E, Chillón MC, et al: MYD88 L265P is amarker highly characteristic of, but not restricted to,Waldenström's macroglobulinemia. Leukemia 27: 1722-1728, 2013
-
(2013)
Leukemia
, vol.27
, pp. 1722-1728
-
-
Jiménez, C.1
Sebastián, E.2
Chillón, M.C.3
-
23
-
-
84879404052
-
MYD88 L265P mutation in Waldenstrom macroglobulinemia
-
Poulain S, Roumier C, Decambron A, et al: MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood 121: 4504-4511, 2013
-
(2013)
Blood
, vol.121
, pp. 4504-4511
-
-
Poulain, S.1
Roumier, C.2
Decambron, A.3
-
24
-
-
84895459238
-
Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
-
Ansell SM, Hodge LS, Secreto FJ, et al: Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. Blood Cancer J 4: E183, 2014
-
(2014)
Blood Cancer J
, vol.4
, pp. e183
-
-
Ansell, S.M.1
Hodge, L.S.2
Secreto, F.J.3
-
25
-
-
84938862553
-
MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia
-
Treon SP, Xu L, Hunter Z: MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med 373: 584-586, 2015
-
(2015)
N Engl J Med
, vol.373
, pp. 584-586
-
-
Treon, S.P.1
Xu, L.2
Hunter, Z.3
-
26
-
-
84915804247
-
MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome
-
Poulain S, Boyle EM, Roumier C, et al: MYD88 L265P mutation contributes to the diagnosis of Bing Neel syndrome. Br J Haematol 167: 506-513, 2014
-
(2014)
Br J Haematol
, vol.167
, pp. 506-513
-
-
Poulain, S.1
Boyle, E.M.2
Roumier, C.3
-
27
-
-
84995444989
-
MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinemia
-
10.1111/bjh.14386 [epub ahead of print on October 17
-
Gustine J, Meid K, Hunter ZR, et al: MYD88 mutations can be used to identify malignant pleural effusions in Waldenström macroglobulinemia. Br J Haematol 10.1111/bjh.14386 [epub ahead of print on October 17, 2016]
-
(2016)
Br J Haematol
-
-
Gustine, J.1
Meid, K.2
Hunter, Z.R.3
-
28
-
-
84897511040
-
The genomic landscape of Waldenstom macroglobulinemia is characterized by highly recurring MYD88 and WHIMlike CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis
-
Hunter ZR, Xu L, Yang G, et al: The genomic landscape of Waldenstom macroglobulinemia is characterized by highly recurring MYD88 and WHIMlike CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood 123: 1637-1646, 2014
-
(2014)
Blood
, vol.123
, pp. 1637-1646
-
-
Hunter, Z.R.1
Xu, L.2
Yang, G.3
-
29
-
-
85016322876
-
Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom's macroglobulinemia, and associated with CXCR4 mutations status
-
Amsterdam, The Netherlands, October (abstr W7
-
Tsakmaklis N: Mutated MYD88 homozygosity is increased in previously treated patients with Waldenstrom's macroglobulinemia, and associated with CXCR4 mutations status. IXth International Workshop on Waldenstrom's Macroglobulinemia, Amsterdam, The Netherlands, October 5-8, 2016 (abstr W7)
-
(2016)
IXth International Workshop on Waldenstrom's Macroglobulinemia
, pp. 5-8
-
-
Tsakmaklis, N.1
-
30
-
-
85016235316
-
Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom's Macroglobulinemia
-
Treon SP, Tsakmaklis N, Meid K, et al: Mutated MYD88 zygosity and CXCR4 mutation status are important determinants of ibrutinib response and progression free survival in Waldenstrom's Macroglobulinemia. Blood 128: 2984, 2016
-
(2016)
Blood
, vol.128
, pp. 2984
-
-
Treon, S.P.1
Tsakmaklis, N.2
Meid, K.3
-
31
-
-
84887396799
-
MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance
-
VarettoniM, Zibellini S, Arcaini L, et al: MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood 122: 2284-2285, 2013
-
(2013)
Blood
, vol.122
, pp. 2284-2285
-
-
VarettoniM Zibellini, S.1
Arcaini, L.2
-
32
-
-
84900443158
-
Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia
-
Treon SP, Cao Y, Xu L, et al: Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood 123: 2791-2796, 2014
-
(2014)
Blood
, vol.123
, pp. 2791-2796
-
-
Treon, S.P.1
Cao, Y.2
Xu, L.3
-
33
-
-
77953714711
-
Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling
-
Lin SC, Lo YC, Wu H: Helical assembly in the MyD88-IRAK4-IRAK2 complex in TLR/IL-1R signalling. Nature 465: 885-890, 2010
-
(2010)
Nature
, vol.465
, pp. 885-890
-
-
Lin, S.C.1
Lo, Y.C.2
Wu, H.3
-
34
-
-
79551686422
-
Oncogenically active MYD88 mutations in human lymphoma
-
Ngo VN, Young RM, Schmitz R, et al: Oncogenically active MYD88 mutations in human lymphoma. Nature 470: 115-119, 2011
-
(2011)
Nature
, vol.470
, pp. 115-119
-
-
Ngo, V.N.1
Young, R.M.2
Schmitz, R.3
-
35
-
-
84883876958
-
A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia
-
Yang G, Zhou Y, Liu X, et al: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood 122: 1222-1232, 2013
-
(2013)
Blood
, vol.122
, pp. 1222-1232
-
-
Yang, G.1
Zhou, Y.2
Liu, X.3
-
36
-
-
84963692137
-
Targeting myddosome assembly in Waldenstrom macroglobulinaemia
-
10.1111/bjh.14103 [epub ahead of print on April 13
-
Liu X, Hunter ZR, Xu L, et al: Targeting myddosome assembly in Waldenstrom macroglobulinaemia. Br J Haematol 10.1111/bjh.14103 [epub ahead of print on April 13, 2016]
-
(2016)
Br J Haematol
-
-
Liu, X.1
Hunter, Z.R.2
Xu, L.3
-
37
-
-
84994683978
-
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib
-
Yang G, Buhrlage SJ, Tan L, et al: HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib. Blood 127: 3237-3252, 2016
-
(2016)
Blood
, vol.127
, pp. 3237-3252
-
-
Yang, G.1
Buhrlage, S.J.2
Tan, L.3
-
38
-
-
84962327986
-
Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia
-
Poulain S, Roumier C, Venet-Caillault A, et al: Genomic landscape of CXCR4 mutations in Waldenström macroglobulinemia. Clin Cancer Res 22: 1480-1488, 2016
-
(2016)
Clin Cancer Res
, vol.22
, pp. 1480-1488
-
-
Poulain, S.1
Roumier, C.2
Venet-Caillault, A.3
-
39
-
-
84958947359
-
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia
-
Xu L, Hunter ZR, Tsakmaklis N, et al: Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia. Br J Haematol 172: 735-744, 2016
-
(2016)
Br J Haematol
, vol.172
, pp. 735-744
-
-
Xu, L.1
Hunter, Z.R.2
Tsakmaklis, N.3
-
40
-
-
84930259756
-
MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
-
Schmidt J, Federmann B, Schindler N, et al: MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity. Br J Haematol 169: 795-803, 2015
-
(2015)
Br J Haematol
, vol.169
, pp. 795-803
-
-
Schmidt, J.1
Federmann, B.2
Schindler, N.3
-
41
-
-
0037656291
-
Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease
-
Hernandez PA, Gorlin RJ, Lukens JN, et al: Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nat Genet 34: 70-74, 2003
-
(2003)
Nat Genet
, vol.34
, pp. 70-74
-
-
Hernandez, P.A.1
Gorlin, R.J.2
Lukens, J.N.3
-
42
-
-
84863670283
-
WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4
-
LiuQ, Chen H, Ojode T, et al: WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4. Blood 120: 181-189, 2012
-
(2012)
Blood
, vol.120
, pp. 181-189
-
-
LiuQ Chen, H.1
Ojode, T.2
-
43
-
-
0030712369
-
Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization
-
Haribabu B, Richardson RM, Fisher I, et al: Regulation of human chemokine receptors CXCR4. Role of phosphorylation in desensitization and internalization. J Biol Chem 272: 28726-28731, 1997
-
(1997)
J Biol Chem
, vol.272
, pp. 28726-28731
-
-
Haribabu, B.1
Richardson, R.M.2
Fisher, I.3
-
44
-
-
84920679727
-
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia
-
Cao Y, Hunter ZR, Liu X, et al: The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's macroglobulinemia. Leukemia 29: 169-176, 2015
-
(2015)
Leukemia
, vol.29
, pp. 169-176
-
-
Cao, Y.1
Hunter, Z.R.2
Liu, X.3
-
45
-
-
84922832325
-
CXCR4 WHIMlike frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 (L265P) -directed survival signalling in Waldenström macroglobulinaemia cells
-
Cao Y, Hunter ZR, Liu X, et al: CXCR4 WHIMlike frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88 (L265P) -directed survival signalling in Waldenström macroglobulinaemia cells. Br J Haematol 168: 701-707, 2015
-
(2015)
Br J Haematol
, vol.168
, pp. 701-707
-
-
Cao, Y.1
Hunter, Z.R.2
Liu, X.3
-
46
-
-
84903647822
-
C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma
-
Roccaro AM, Sacco A, Jimenez C, et al: C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood 123: 4120-4131, 2014
-
(2014)
Blood
, vol.123
, pp. 4120-4131
-
-
Roccaro, A.M.1
Sacco, A.2
Jimenez, C.3
-
47
-
-
77957946398
-
ARID1A mutations in endometriosis-associated ovarian carcinomas
-
Wiegand KC, Shah SP, Al-Agha OM, et al: ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 363: 1532-1543, 2010
-
(2010)
N Engl J Med
, vol.363
, pp. 1532-1543
-
-
Wiegand, K.C.1
Shah, S.P.2
Al-Agha, O.M.3
-
48
-
-
80155131218
-
ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers
-
Guan B, Wang T-L, Shih IeM: ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res 71: 6718-6727, 2011
-
(2011)
Cancer Res
, vol.71
, pp. 6718-6727
-
-
Guan, B.1
Wang, T.-L.2
Shih IeM.3
-
49
-
-
84923407069
-
B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells
-
Seda V, Mraz M: B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol 94: 193-205, 2015
-
(2015)
Eur J Haematol
, vol.94
, pp. 193-205
-
-
Seda, V.1
Mraz, M.2
-
50
-
-
84938994998
-
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
-
Wilson WH, Young RM, Schmitz R, et al: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21: 922-926, 2015
-
(2015)
Nat Med
, vol.21
, pp. 922-926
-
-
Wilson, W.H.1
Young, R.M.2
Schmitz, R.3
-
51
-
-
84959473340
-
Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling
-
Argyropoulos KV, Vogel R, Ziegler C, et al: Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling. Leukemia 30: 1116-1125, 2016
-
(2016)
Leukemia
, vol.30
, pp. 1116-1125
-
-
Argyropoulos, K.V.1
Vogel, R.2
Ziegler, C.3
-
52
-
-
0032492994
-
Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes
-
Chan VWF, Lowell CA, DeFranco AL: Defective negative regulation of antigen receptor signaling in Lyn-deficient B lymphocytes. Curr Biol 8: 545-553, 1998
-
(1998)
Curr Biol
, vol.8
, pp. 545-553
-
-
Chan, V.W.F.1
Lowell, C.A.2
DeFranco, A.L.3
-
53
-
-
85016265468
-
Genetic characterization of Waldenstrom macroglobulinemia by next generation sequencing: An analysis of fourteen genes in a series of 61 patients
-
(abstr 2971)
-
Jimenez C, Prieto-Conde I, García-Álvarez M, et al: Genetic characterization of Waldenstrom macroglobulinemia by next generation sequencing: An analysis of fourteen genes in a series of 61 patients. Blood 126, 2015 (abstr 2971)
-
(2015)
Blood
, vol.126
-
-
Jimenez, C.1
Prieto-Conde, I.2
García-Álvarez, M.3
-
54
-
-
85031724148
-
Whole-exome sequencing of Waldenstrom Macroglobulinemia transformation into aggressive lymphoma
-
(abstr 4101)
-
Alonso S, Jimenez C, Alcoceba M, et al: Whole-exome sequencing of Waldenstrom Macroglobulinemia transformation into aggressive lymphoma. Blood 128, 2016 (abstr 4101)
-
(2016)
Blood
, vol.128
-
-
Alonso, S.1
Jimenez, C.2
Alcoceba, M.3
-
55
-
-
80052029516
-
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
-
Morin RD, Mendez-Lago M, Mungall AJ, et al: Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476: 298-303, 2011
-
(2011)
Nature
, vol.476
, pp. 298-303
-
-
Morin, R.D.1
Mendez-Lago, M.2
Mungall, A.J.3
-
56
-
-
84857942952
-
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by wholeexome sequencing
-
Lohr JG, Stojanov P, Lawrence MS, et al: Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by wholeexome sequencing. Proc Natl Acad Sci USA 109: 3879-3884, 2012
-
(2012)
Proc Natl Acad Sci USA
, vol.109
, pp. 3879-3884
-
-
Lohr, J.G.1
Stojanov, P.2
Lawrence, M.S.3
-
57
-
-
84905995241
-
Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia
-
Zhou Y, Liu X, Xu L, et al: Transcriptional repression of plasma cell differentiation is orchestrated by aberrant over-expression of the ETS factor SPIB in Waldenström macroglobulinaemia. Br J Haematol 166: 677-689, 2014
-
(2014)
Br J Haematol
, vol.166
, pp. 677-689
-
-
Zhou, Y.1
Liu, X.2
Xu, L.3
-
58
-
-
33847185954
-
Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals
-
Gutiérrez NC, Ocio EM, de Las Rivas J, et al: Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: Comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia 21: 541-549, 2007
-
(2007)
Leukemia
, vol.21
, pp. 541-549
-
-
Gutiérrez, N.C.1
Ocio, E.M.2
De Las Rivas, J.3
-
59
-
-
33750619898
-
Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma
-
Chng WJ, Schop RF, Price-Troska T, et al: Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood 108: 2755-2763, 2006
-
(2006)
Blood
, vol.108
, pp. 2755-2763
-
-
Chng, W.J.1
Schop, R.F.2
Price-Troska, T.3
-
60
-
-
84981495262
-
Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia
-
Hunter ZR, Xu L, Yang G, et al: Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood 128: 827-838, 2016
-
(2016)
Blood
, vol.128
, pp. 827-838
-
-
Hunter, Z.R.1
Xu, L.2
Yang, G.3
-
61
-
-
84981510933
-
Biologically meaningful changes in cytokine and chemokine production following Ibrutinib therapy in Waldenstrom's Macroglobulinemia
-
(abstr P312)
-
Vos JM, Tsakmaklis N, Brodsky PS, et al: Biologically meaningful changes in cytokine and chemokine production following Ibrutinib therapy in Waldenstrom's Macroglobulinemia. Haematologica 101: 101, 2016 (abstr P312)
-
(2016)
Haematologica
, vol.101
, pp. 101
-
-
Vos, J.M.1
Tsakmaklis, N.2
Brodsky, P.S.3
-
63
-
-
84987788570
-
Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia
-
Leblond V, Kastritis E, Advani R, et al: Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood 128: 1321-1328, 2016
-
(2016)
Blood
, vol.128
, pp. 1321-1328
-
-
Leblond, V.1
Kastritis, E.2
Advani, R.3
-
64
-
-
84927155030
-
Ibrutinib in previously treated Waldenström's macroglobulinemia
-
Treon SP, Tripsas CK, Meid K, et al: Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med 372: 1430-1440, 2015
-
(2015)
N Engl J Med
, vol.372
, pp. 1430-1440
-
-
Treon, S.P.1
Tripsas, C.K.2
Meid, K.3
-
65
-
-
85016288716
-
Single agent ibrutinib in rituximab-refractory patients with Waldenström's macroglobulinemia: Results from a multicenter, open-label phase 3 substudy (iNNOVATETM)
-
in press)
-
Dimopoulos MA, Trotman J, Tedeschi A, et al: Single agent ibrutinib in rituximab-refractory patients with Waldenström's macroglobulinemia: Results from a multicenter, open-label phase 3 substudy (iNNOVATETM). Lancet Oncol (in press)
-
Lancet Oncol
-
-
Dimopoulos, M.A.1
Trotman, J.2
Tedeschi, A.3
-
66
-
-
85016243664
-
Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia
-
10.1158/1078-0432.CCR-16-1918 [ epub ahead of print on November 11
-
Treon SP, Meid K, Tripsas C, et al: Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom Macroglobulinemia. Clin Cancer Res 10.1158/1078-0432.CCR-16-1918 [epub ahead of print on November 11, 2016]
-
(2016)
Clin Cancer Res
-
-
Treon, S.P.1
Meid, K.2
Tripsas, C.3
-
67
-
-
84904916820
-
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia
-
Treon SP, Tripsas CK, Meid K, et al: Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood 124: 503-510, 2014
-
(2014)
Blood
, vol.124
, pp. 503-510
-
-
Treon, S.P.1
Tripsas, C.K.2
Meid, K.3
-
68
-
-
85038420830
-
Ixazomib, dexamethasone, and rituximab (IDR) as primary therapy for symptomatic symptomatic Waldenstrom macroglobulinemia
-
(abstr 2956)
-
Castillo JJ: Ixazomib, dexamethasone, and rituximab (IDR) as primary therapy for symptomatic symptomatic Waldenstrom macroglobulinemia. Blood 128, 2016 (abstr 2956)
-
(2016)
Blood
, vol.128
-
-
Castillo, J.J.1
-
69
-
-
84925502851
-
Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers
-
Bitler BG, Aird KM, Garipov A, et al: Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nat Med 21: 231-238, 2015
-
(2015)
Nat Med
, vol.21
, pp. 231-238
-
-
Bitler, B.G.1
Aird, K.M.2
Garipov, A.3
-
70
-
-
84940050343
-
How I treat Waldenström macroglobulinemia
-
Treon SP: How I treat Waldenström macroglobulinemia. Blood 126: 721-732, 2015
-
(2015)
Blood
, vol.126
, pp. 721-732
-
-
Treon, S.P.1
-
71
-
-
84931563809
-
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells
-
Cao Y, Yang G, Hunter ZR, et al: The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 170: 134-138, 2015
-
(2015)
Br J Haematol
, vol.170
, pp. 134-138
-
-
Cao, Y.1
Yang, G.2
Hunter, Z.R.3
-
72
-
-
84997558826
-
A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma
-
(abstr)
-
Gerecitano JF, Roberts AW, Seymour JF et al: A phase 1 study of venetoclax (ABT-199/GDC-0199) monotherapy in patients with relapsed/refractory non-Hodgkin lymphoma. Blood 126: 254, 2015 (abstr)
-
(2015)
Blood
, vol.126
, pp. 254
-
-
Gerecitano, J.F.1
Roberts, A.W.2
Seymour, J.F.3
|